Copyright Reports & Markets. All rights reserved.

RNA-Based Therapeutics and Vaccines-Global Market Status and Trend Report 2016-2026

Request for Sample of this report
Buy now

Table of Contents

    Chapter 1 Overview of RNA-Based Therapeutics and Vaccines

    • 1.1 Definition of RNA-Based Therapeutics and Vaccines in This Report
    • 1.2 Commercial Types of RNA-Based Therapeutics and Vaccines
      • 1.2.1 RNA-Based Therapeutics
      • 1.2.2 RNA-Based Vaccines
    • 1.3 Downstream Application of RNA-Based Therapeutics and Vaccines
      • 1.3.1 Oncology
      • 1.3.2 Immunology
      • 1.3.3 Ophthalmology
      • 1.3.4 Cardiovascular Diseases
      • 1.3.5 Infectious Diseases
      • 1.3.6 Genetic Diseases
      • 1.3.7 Others
    • 1.4 Development History of RNA-Based Therapeutics and Vaccines
    • 1.5 Market Status and Trend of RNA-Based Therapeutics and Vaccines 2016-2026
      • 1.5.1 Global RNA-Based Therapeutics and Vaccines Market Status and Trend 2016-2026
      • 1.5.2 Regional RNA-Based Therapeutics and Vaccines Market Status and Trend 2016-2026

    Chapter 2 Global Market Status and Forecast by Regions

    • 2.1 Market Development of RNA-Based Therapeutics and Vaccines 2016-2021
    • 2.2 Production Market of RNA-Based Therapeutics and Vaccines by Regions
      • 2.2.1 Production Volume of RNA-Based Therapeutics and Vaccines by Regions
      • 2.2.2 Production Value of RNA-Based Therapeutics and Vaccines by Regions
    • 2.3 Demand Market of RNA-Based Therapeutics and Vaccines by Regions
    • 2.4 Production and Demand Status of RNA-Based Therapeutics and Vaccines by Regions
      • 2.4.1 Production and Demand Status of RNA-Based Therapeutics and Vaccines by Regions 2016-2021
      • 2.4.2 Import and Export Status of RNA-Based Therapeutics and Vaccines by Regions 2016-2021

    Chapter 3 Global Market Status and Forecast by Types

    • 3.1 Production Volume of RNA-Based Therapeutics and Vaccines by Types
    • 3.2 Production Value of RNA-Based Therapeutics and Vaccines by Types
    • 3.3 Market Forecast of RNA-Based Therapeutics and Vaccines by Types

    Chapter 4 Global Market Status and Forecast by Downstream Industry

    • 4.1 Demand Volume of RNA-Based Therapeutics and Vaccines by Downstream Industry
    • 4.2 Market Forecast of RNA-Based Therapeutics and Vaccines by Downstream Industry

    Chapter 5 Market Driving Factor Analysis of RNA-Based Therapeutics and Vaccines

    • 5.1 Global Economy Situation and Trend Overview
    • 5.2 RNA-Based Therapeutics and Vaccines Downstream Industry Situation and Trend Overview

    Chapter 6 RNA-Based Therapeutics and Vaccines Market Competition Status by Major Manufacturers

    • 6.1 Production Volume of RNA-Based Therapeutics and Vaccines by Major Manufacturers
    • 6.2 Production Value of RNA-Based Therapeutics and Vaccines by Major Manufacturers
    • 6.3 Basic Information of RNA-Based Therapeutics and Vaccines by Major Manufacturers
      • 6.3.1 Headquarters Location and Established Time of RNA-Based Therapeutics and Vaccines Major Manufacturer
      • 6.3.2 Employees and Revenue Level of RNA-Based Therapeutics and Vaccines Major Manufacturer
    • 6.4 Market Competition News and Trend
      • 6.4.1 Merger, Consolidation or Acquisition News
      • 6.4.2 Investment or Disinvestment News
      • 6.4.3 New Product Development and Launch

    Chapter 7 RNA-Based Therapeutics and Vaccines Major Manufacturers Introduction and Market Data

    • 7.1 Alnylam Pharmaceuticals
      • 7.1.1 Company profile
      • 7.1.2 Representative RNA-Based Therapeutics and Vaccines Product
      • 7.1.3 RNA-Based Therapeutics and Vaccines Sales, Revenue, Price and Gross Margin of Alnylam Pharmaceuticals
    • 7.2 Arbutus Biopharma
      • 7.2.1 Company profile
      • 7.2.2 Representative RNA-Based Therapeutics and Vaccines Product
      • 7.2.3 RNA-Based Therapeutics and Vaccines Sales, Revenue, Price and Gross Margin of Arbutus Biopharma
    • 7.3 Arrowhead Pharmaceuticals
      • 7.3.1 Company profile
      • 7.3.2 Representative RNA-Based Therapeutics and Vaccines Product
      • 7.3.3 RNA-Based Therapeutics and Vaccines Sales, Revenue, Price and Gross Margin of Arrowhead Pharmaceuticals
    • 7.4 BioNTech
      • 7.4.1 Company profile
      • 7.4.2 Representative RNA-Based Therapeutics and Vaccines Product
      • 7.4.3 RNA-Based Therapeutics and Vaccines Sales, Revenue, Price and Gross Margin of BioNTech
    • 7.5 CureVac
      • 7.5.1 Company profile
      • 7.5.2 Representative RNA-Based Therapeutics and Vaccines Product
      • 7.5.3 RNA-Based Therapeutics and Vaccines Sales, Revenue, Price and Gross Margin of CureVac
    • 7.6 Dicerna Pharmaceuticals
      • 7.6.1 Company profile
      • 7.6.2 Representative RNA-Based Therapeutics and Vaccines Product
      • 7.6.3 RNA-Based Therapeutics and Vaccines Sales, Revenue, Price and Gross Margin of Dicerna Pharmaceuticals
    • 7.7 Regulus Therapeutics
      • 7.7.1 Company profile
      • 7.7.2 Representative RNA-Based Therapeutics and Vaccines Product
      • 7.7.3 RNA-Based Therapeutics and Vaccines Sales, Revenue, Price and Gross Margin of Regulus Therapeutics
    • 7.8 Marina Biotech
      • 7.8.1 Company profile
      • 7.8.2 Representative RNA-Based Therapeutics and Vaccines Product
      • 7.8.3 RNA-Based Therapeutics and Vaccines Sales, Revenue, Price and Gross Margin of Marina Biotech
    • 7.9 MiRagen Therapeutics
      • 7.9.1 Company profile
      • 7.9.2 Representative RNA-Based Therapeutics and Vaccines Product
      • 7.9.3 RNA-Based Therapeutics and Vaccines Sales, Revenue, Price and Gross Margin of MiRagen Therapeutics
    • 7.10 Moderna Therapeutics
      • 7.10.1 Company profile
      • 7.10.2 Representative RNA-Based Therapeutics and Vaccines Product
      • 7.10.3 RNA-Based Therapeutics and Vaccines Sales, Revenue, Price and Gross Margin of Moderna Therapeutics
    • 7.11 Quark Pharmaceuticals
      • 7.11.1 Company profile
      • 7.11.2 Representative RNA-Based Therapeutics and Vaccines Product
      • 7.11.3 RNA-Based Therapeutics and Vaccines Sales, Revenue, Price and Gross Margin of Quark Pharmaceuticals
    • 7.12 Roche
      • 7.12.1 Company profile
      • 7.12.2 Representative RNA-Based Therapeutics and Vaccines Product
      • 7.12.3 RNA-Based Therapeutics and Vaccines Sales, Revenue, Price and Gross Margin of Roche
    • 7.13 Sylentis
      • 7.13.1 Company profile
      • 7.13.2 Representative RNA-Based Therapeutics and Vaccines Product
      • 7.13.3 RNA-Based Therapeutics and Vaccines Sales, Revenue, Price and Gross Margin of Sylentis

    Chapter 8 Upstream and Downstream Market Analysis of RNA-Based Therapeutics and Vaccines

    • 8.1 Industry Chain of RNA-Based Therapeutics and Vaccines
    • 8.2 Upstream Market and Representative Companies Analysis
    • 8.3 Downstream Market and Representative Companies Analysis

    Chapter 9 Cost and Gross Margin Analysis of RNA-Based Therapeutics and Vaccines

    • 9.1 Cost Structure Analysis of RNA-Based Therapeutics and Vaccines
    • 9.2 Raw Materials Cost Analysis of RNA-Based Therapeutics and Vaccines
    • 9.3 Labor Cost Analysis of RNA-Based Therapeutics and Vaccines
    • 9.4 Manufacturing Expenses Analysis of RNA-Based Therapeutics and Vaccines

    Chapter 10 Marketing Status Analysis of RNA-Based Therapeutics and Vaccines

    • 10.1 Marketing Channel
      • 10.1.1 Direct Marketing
      • 10.1.2 Indirect Marketing
      • 10.1.3 Marketing Channel Development Trend
    • 10.2 Market Positioning
      • 10.2.1 Pricing Strategy
      • 10.2.2 Brand Strategy
      • 10.2.3 Target Client
    • 10.3 Distributors/Traders List

    Chapter 11 Report Conclusion

      Chapter 12 Research Methodology and Reference

      • 12.1 Methodology/Research Approach
        • 12.1.1 Research Programs/Design
        • 12.1.2 Market Size Estimation
        • 12.1.3 Market Breakdown and Data Triangulation
      • 12.2 Data Source
        • 12.2.1 Secondary Sources
        • 12.2.2 Primary Sources

      Report Summary

      RNA-Based Therapeutics and Vaccines-Global Market Status and Trend Report 2016-2026 offers a comprehensive analysis on RNA-Based Therapeutics and Vaccines industry, standing on the readers’ perspective, delivering detailed market data and penetrating insights. No matter the client is industry insider, potential entrant or investor, the report will provides useful data and information. Key questions answered by this report include:

      Worldwide and Regional Market Size of RNA-Based Therapeutics and Vaccines 2016-2021, and development forecast 2022-2026
      Main manufacturers/suppliers of RNA-Based Therapeutics and Vaccines worldwide, with company and product introduction, position in the RNA-Based Therapeutics and Vaccines market
      Market status and development trend of RNA-Based Therapeutics and Vaccines by types and applications
      Cost and profit status of RNA-Based Therapeutics and Vaccines, and marketing status
      Market growth drivers and challengesSince the COVID-19 virus outbreak in December 2019, the disease has spread to almost 100 countries around the globe with the World Health Organization declaring it a public health emergency.The global impacts of the coronavirus disease 2019 (COVID-19) are already starting to be felt, and will significantly affect the Ammonium RNA-Based Therapeutics and Vaccines market in 2020.COVID-19 can affect the global economy in three main ways: by directly affecting production and demand, by creating supply chain and market disruption, and by its financial impact on firms and financial markets.The outbreak of COVID-19 has brought effects on many aspects, like flight cancellations; travel bans and quarantines; restaurants closed; all indoor events restricted; over forty countries state of emergency declared; massive slowing of the supply chain; stock market volatility; falling business confidence, growing panic among the population, and uncertainty about future.This report also analyses the impact of Coronavirus COVID-19 on the RNA-Based Therapeutics and Vaccines industry.

      The report segments the global RNA-Based Therapeutics and Vaccines market as:

      Global RNA-Based Therapeutics and Vaccines Market: Regional Segment Analysis (Regional Production Volume, Consumption Volume, Revenue and Growth Rate 2016-2026):
      North America
      Europe
      China
      Japan
      Rest APAC
      Latin America

      Global RNA-Based Therapeutics and Vaccines Market: Type Segment Analysis (Consumption Volume, Average Price, Revenue, Market Share and Trend 2016-2026):
      RNA-Based Therapeutics
      RNA-Based Vaccines

      Global RNA-Based Therapeutics and Vaccines Market: Application Segment Analysis (Consumption Volume and Market Share 2016-2026; Downstream Customers and Market Analysis)
      Oncology
      Immunology
      Ophthalmology
      Cardiovascular Diseases
      Infectious Diseases
      Genetic Diseases
      Others

      Global RNA-Based Therapeutics and Vaccines Market: Manufacturers Segment Analysis (Company and Product introduction, RNA-Based Therapeutics and Vaccines Sales Volume, Revenue, Price and Gross Margin):
      Alnylam Pharmaceuticals
      Arbutus Biopharma
      Arrowhead Pharmaceuticals
      BioNTech
      CureVac
      Dicerna Pharmaceuticals
      Regulus Therapeutics
      Marina Biotech
      MiRagen Therapeutics
      Moderna Therapeutics
      Quark Pharmaceuticals
      Roche
      Sylentis

      In a word, the report provides detailed statistics and analysis on the state of the industry; and is a valuable source of guidance and direction for companies and individuals interested in the market.
      Buy now